

PCT.
IAP6 Rec'd PCT/PTO 21 FEB 2007

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/529,655-Conf. #5836
	Filing Date	September 30, 2003
	First Named Inventor	Matthew J. Scanlan
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	L0461.70156US00

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): Return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Janice A. Vatland, Ph.D.		
Date	February 16, 2007	Reg. No.	52,318

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: February 16, 2007	Signature: (Emily E. Zukauskas)



Docket No.: L0461.70156US00
(PATENT)


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Matthew J. Scanlan et al.
Serial No.: 10/529,655
Confirmation No.: 5836
Filed: September 30, 2003
For: HUMAN SARCOMA-ASSOCIATED ANTIGENS
Examiner: Not Yet Assigned
Art Unit: N/A

Certificate of Mailing Under 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 16, 2007


Emily E. Zakauskas

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Copies of the references on the PTO/SB/08 are not provided.

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in prior application number 10/260708 filed September 30, 2002 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does (do) not waive the confidentiality provisions of 35 U.S.C. § 122.

Application Number	Filing Date	Inventor	Docket No.
10/260708	09-30-2002	Scanlan et al.	L0461.70138US00

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this

application by this firm) to our Deposit Account No. 23/2825, under Docket No. L0461.70156US00. A duplicate copy of this paper is enclosed.

Dated: February 16, 2007

Respectfully submitted,

By 

Janice A. Vatland, Ph.D.

Registration No.: 52,318

WOLF, GREENFIELD & SACKS, P.C.

Federal Reserve Plaza

600 Atlantic Avenue

Boston, Massachusetts 02210-2206

(617) 646-8000



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/529,655-Conf. #5836	
			Filing Date	September 30, 2003	
			First Named Inventor	Matthew J. Scanlan	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	4	Attorney Docket Number	L0461.70156US00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1*	US-6,392,019	05-21-2002	Ford et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B2**	WO-2004/031354-A2	04-15-2004	Ludwig Institute for Cancer Research		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with a double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1**	GENBANK Submission; NIH/NCBI, Accession No. AY211909. Lee et al. March 23, 2003.			
	C2**	GENBANK Submission; NIH/NCBI, Accession No. AY211910. Lee et al. March 23, 2003.			
	C3**	GENBANK Submission; NIH/NCBI, Accession No. AY211911. Lee et al. March 23, 2003.			
	C4**	GENBANK Submission; NIH/NCBI, Accession No. AY211912. Lee et al. March 23, 2003.			
	C5**	GENBANK Submission; NIH/NCBI, Accession No. AY211913. Lee et al. March 23, 2003.			
	C6**	GENBANK Submission; NIH/NCBI, Accession No. AY211914. Lee et al. March 23, 2003.			
	C7**	GENBANK Submission; NIH/NCBI, Accession No. AY211915. Lee et al. March 23, 2003.			
	C8**	GENBANK Submission; NIH/NCBI, Accession No. AY211916. Lee et al. March 23, 2003.			
	C9**	GENBANK Submission; NIH/NCBI, Accession No. AY211917. Lee et al. March 23, 2003.			
	C10**	GENBANK Submission; NIH/NCBI, Accession No. AY211918. Lee et al. March 23, 2003.			
	C11**	GENBANK Submission; NIH/NCBI, Accession No. AY211919. Lee et al. March 23, 2003.			
	C12**	GENBANK Submission; NIH/NCBI, Accession No. AY211920. Lee et al. March 23, 2003.			
	C13**	GENBANK Submission; NIH/NCBI, Accession No. AY211921. Lee et al. March 23, 2003.			
	C14**	GENBANK Submission; NIH/NCBI, Accession No. AY211922. Lee et al. March 23, 2003.			
	C15**	GENBANK Submission; NIH/NCBI, Accession No. AY211923. Lee et al. March 23, 2003.			
	C16**	GENBANK Submission; NIH/NCBI, Accession No. AY211924. Lee et al. March 23, 2003.			
	C17**	GENBANK Submission; NIH/NCBI, Accession No. AY211925. Lee et al. March 23, 2003.			
	C18**	GENBANK Submission; NIH/NCBI, Accession No. AY211926. Lee et al. March 23, 2003.			
	C19**	GENBANK Submission; NIH/NCBI, Accession No. AY211927. Lee et al. March 23, 2003.			
	C20**	GENBANK Submission; NIH/NCBI, Accession No. AY211928. Lee et al. March 23, 2003.			
	C21**	GENBANK Submission; NIH/NCBI, Accession No. AY211929. Lee et al. March 23, 2003.			
	C22**	GENBANK Submission; NIH/NCBI, Accession No. AY211930. Lee et al. March 23, 2003.			

Examiner Signature	Date Considered
-----------------------	--------------------

1144359.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/529,655-Conf. #5836	
			Filing Date	September 30, 2003	
			First Named Inventor	Matthew J. Scanlan	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	4	Attorney Docket Number	L0461.70156US00

C23**	GENBANK Submission; NIH/NCBI, Accession No. AY211931. Lee et al. March 23, 2003.	
C24**	GENBANK Submission; NIH/NCBI, Accession No. AA909915. Last updated May 19, 1998.	
C25**	GENBANK Submission; NIH/NCBI, Accession No. AW893050. Last updated September 28, 2004.	
C26**	GENBANK Submission; NIH/NCBI, Accession No. AK098602. Oshima et al. September 14, 2006.	
C27**	GENBANK Submission; NIH/NCBI, Accession No. BI465380. Last updated August 21, 2006.	
C28**	GENBANK Submission; NIH/NCBI, Accession No. BG771667. Last updated May 15, 2001.	
C29**	GENBANK Submission; NIH/NCBI, Accession No. AA906131. Last updated May 19, 1998.	
C30**	GENBANK Submission; NIH/NCBI, Accession No. BC034320. Strausberg et al. July 17, 2006.	
C31**	GENBANK Submission; NIH/NCBI, Accession No. NM_152578. Lee et al. November 17, 2006.	
C32**	GENBANK Submission; NIH/NCBI, Accession No. BX098898. Last updated February 6, 2003.	
C33**	GENBANK Submission; NIH/NCBI, Accession No. CV024823. Last updated August 20, 2004.	
C34**	GENBANK Submission; NIH/NCBI, Accession No. BP370444. Last updated April 24, 2006.	
C35**	GENBANK Submission; NIH/NCBI, Accession No. DB482835. Last updated March 30, 2006.	
C36**	GENBANK Submission; NIH/NCBI, Accession No. DB551686. Last updated July 10, 2006.	
C37**	GENBANK Submission; NIH/NCBI, Accession No. DB450405. Last updated April 13, 2006.	
C38**	GENBANK Submission; NIH/NCBI, Accession No. XM_098959. August 1, 2002.	
C39**	GENBANK Submission; NIH/NCBI, Accession No. XP_150408. February 24, 2003.	
C40**	GENBANK Submission; NIH/NCBI, Accession No. AY214130. Lee et al. March 11, 2003.	
C41**	GENBANK Submission; NIH/NCBI, Accession No. NW_042622. Waterston et al. April 28, 2006.	
C42**	[No Author Listed] 1997/1998 Stratagene Catalog	
C43**	Cancer Immunome Database. SEREX-Sequence Information. Serex ID: 2356. Sequence Name: NY-SAR-36. Last updated September 12, 2002. www2.licr.org/CancerImmunomeDB/SEREX_ShowSequence.php?SerexId=2356 .	
C44**	Cancer Immunome Database. SEREX-Sequence Information. Serex ID: 2368. Sequence Name: NY-SAR-48. Last updated September 12, 2002. www2.licr.org/CancerImmunomeDB/SEREX_ShowSequence.php?SerexId=2368 .	
C45**	AHO et al., Isolation, expression, and chromosomal localization of the human mitochondrial capsule selenoprotein gene (MCSP). Genomics. 1996 Mar 1;32(2):184-90.	
C46**	ANTONESCU et al., MAGE antigen expression in monophasic and biphasic synovial sarcoma. Hum Pathol. 2002 Feb;33(2):225-9.	
C47**	BOEL et al., BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995 Feb;2(2):167-75.	
C48**	CHEN et al., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8.	
C49**	CHEN et al., Identification of human tumor antigens by serological expression cloning. In: Principles and Practice of Biologic Therapy of Cancer. S.A. Rosenberg, ed. Philadelphia: Lippincott Williams & Wilkins. 2000:557-70.	
C50**	CHEN et al., Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6919-23.	
C51**	CONRAD et al., Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J Exp Clin Cancer Res. 1999 Jun;18(2):225-32.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/529,655-Conf. #5836
				Filing Date	September 30, 2003
				First Named Inventor	Matthew J. Scanlan
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	4	Attorney Docket Number	L0461.70156US00

C52**	COX et al., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science. 1994 Apr 29;264(5159):716-9.	
C53**	DOMENJOURD et al., Sequence of human protamine 2 cDNA. Nucleic Acids Res. 1988 Aug 11;16(15):7733.	
C54**	GARRIDO et al., MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117-58.	
C55**	GAUGLER et al., Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994 Mar 1;179(3):921-30.	
C56**	GURE et al., SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer. 1997 Sep 17;72(6):965-71.	
C57**	HOFFMANN et al., The P-domain or trefoil motif: a role in renewal and pathology of mucous epithelia? Trends Biochem. 1993 Jul;18(7):239-43.	
C58**	JAGER et al., Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 2001 Mar 1;61(5):2055-61.	
C59**	JAGER et al., Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. Cancer Res. 2000 Jul 1;60(13):3584-91.	
C60**	JUNGBLUTH et al., Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer. 2001 Oct 15;94(2):252-6.	
C61**	JUNGBLUTH et al., Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001 Jun 15;92(6):856-60.	
C62**	JUNGBLUTH et al., Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer. 2000 Feb 15;85(4):460-5.	
C63**	KAWAKAMI et al., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515-9.	
C64**	KIURU et al., Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 2002 Aug 15;62(16):4554-7.	
C65**	LEE et al., Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6.	
C66**	LETHE et al., LAGE-1, a new gene with tumor specificity. Int J Cancer. 1998 Jun 10;76(6):903-8.	
C67**	LI et al., Molecular cloning of a novel tissue-specific gene from human nasopharyngeal epithelium. Gene. 1999 Sep 3;237(1):235-40.	
C68**	PASCOLO et al., A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 2001 May 15;61(10):4072-7.	
C69**	SAHIN et al., Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3.	
C70**	SAHIN et al., Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer. 1998 Oct 29;78(3):387-9.	
C71**	SCANLAN et al., Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer. 1998 May 29;76(5):652-8.	
C72**	SCANLAN et al., Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett. 2000 Mar 31;150(2):155-64.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/529,655-Conf. #5836
				Filing Date	September 30, 2003
				First Named Inventor	Matthew J. Scanlan
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	4	Attorney Docket Number	L0461.70156US00

C73**	SCANLAN et al., Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002 Jul 15;62(14):4041-7.	
C74**	SCANLAN et al., Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 1999 Nov 12;83(4):456-64.	
C75**	SCANLAN et al., Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 2001 Mar 30;1:4.	
C76**	SKIPPER et al., An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med. 1996 Feb 1;183(2):527-34.	
C77**	STOCKERT et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998 Apr 20;187(8):1349-54.	
C78**	TOCKMAN et al., Considerations in bringing a cancer biomarker to clinical application. Cancer Res. 1992 May 1;52(9 Suppl):2711s-2718s.	
C79**	TOMLINSON et al., Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002 Apr;30(4):406-10.	
C80**	TURECI et al., Expression of SSX genes in human tumors. Int J Cancer. 1998 Jul 3;77(1):19-23.	
C81**	VAN DEN EYNDE et al., A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med. 1995 Sep 1;182(3):689-98.	
C82**	VAN DEN EYNDE et al., T cell defined tumor antigens. Curr Opin Immunol. 1997 Oct;9(5):684-93.	
C83**	VAN DER BRUGGEN et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13;254(5038):1643-7.	
C84**	WILDNER et al., Enzyme prodrug gene therapy: synergistic use of the herpes simplex virus-cellular thymidine kinase/ganciclovir system and thymidylate synthase inhibitors for the treatment of colon cancer. Cancer Res. 1999 Oct 15;59(20):5233-8.	
C85**	WESTERHUIS et al., Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). J Am Soc Nephrol. 1999 Apr;10(4):770-8.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/92 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/529,655

Attorney Docket No.: L0461.70156US00

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 16, 2007
Date


Signature

Emily E. Zukauskas

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 646-8373
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (87 References) (4 pages)